Abbott to pay $175 million for Ibis
This article was originally published in Scrip
Executive Summary
Abbott is to pay $175 million for Ibis Biosciences after it exercised its option to buy the remaining equity ownership in the Isis Pharmaceuticals subsidiary. The move will strengthen Abbott's capabilities in identifying infectious agents in hospital and clinical settings. Earlier this year, Abbott invested $40 million in Ibis in exchange for 18.6% of Ibis's equity. Isis will receive earn-out payments tied to post-closing sales of Ibis systems, including instruments and assay kits. The transaction is expected to close in January 2009. Ibis's technology also has biodefence applications and use in microbial forensics (Scrip Online, July 3rd, 2008).
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.